Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.

ABSTRACT: Described as the 'single largest unmet need in cardiovascular medicine', heart failure with preserved ejection fraction (HFpEF) remains an untreatable disease currently representing 65% of new heart failure diagnoses. HFpEF is more frequent among women and associates with a poor prognosis and unsustainable healthcare costs. Moreover, the variability in HFpEF phenotypes amplifies complexity and difficulties in the approach. In this perspective, unveiling novel molecular targets is imperative. Epigenetic modifications-defined as changes of DNA, histones, and non-coding RNAs (ncRNAs)-represent a molecular framework through which the environment modulates gene expression. Epigenetic signals acquired over the lifetime lead to chromatin remodelling and affect transcriptional programmes underlyin

SUBMITTER: Hamdani N 

PROVIDER: S-EPMC8921660 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature